Used it once and it cleared up the urinary tract infection. The second time I used it I developed tendonitis.
I react to every antibiotic out there. Levaquin is the only one I can take with no side effects. This is an excellent drug and gets rid of my urinary tract infections fast, with no yeast infection after it.
Levaquin (levofloxacin) for Bacterial Infection: My doctor prescribed Levaquin (500 mg for 10 days) because she said it would take care of both my UTI and sore throat without having to take 2 different antibiotics. After the first two days I felt better, but the 3rd day my sore throat returned and I began to ache all over like flu symptoms. The 4th and 5th days the calves of my legs hurt, and the 5th night I couldn't sleep because my calves were hurting so badly, I wondered if I had blood clots. Today (6th), my calves, neck and ankles hurt -- I just took my 6th pill and my upper lip is swelling is looked up the side effects and it seems I have most of them. The first 2 days I was very short of breath when walking and climbing the stairs and always have had a headache -- will stop!
poniedziałek, 5 listopada 2012
Levaquin (levofloxacin) for Bronchitis
On my third day with Levaquin. Only problem that I am having is insomnia. Tired during the day, completely awake at night. Cough is pretty much gone. I feel great, just need to go to bed.
I have been using this for 4 days now. I was taking this for bronchitis. My throat was so sore from an unproductive cough. After the first day of using this, the soreness in my throat went away. Everything is now loosening and feel so much better. I haven't had much of an appetite but have not had any trouble sleeping. I have not experienced any of the symptoms other reviewers have noted.
I had a very negative reaction to this antibiotic. Extreme fatigue, continuing muscle weakness (after approximately 5 weeks), very vivid and frightening dreams, slow improvement in my bronchitis. I will never take this again.
I was perscribed Levaquin for bronchitis and it was completely effective. Now six months later I have developed a full compliment of the drugs side effects. Thrush, hives, yeast infection(vaginal), leg cramps and a knotted tendon. I am 65.
I have been using this for 4 days now. I was taking this for bronchitis. My throat was so sore from an unproductive cough. After the first day of using this, the soreness in my throat went away. Everything is now loosening and feel so much better. I haven't had much of an appetite but have not had any trouble sleeping. I have not experienced any of the symptoms other reviewers have noted.
I had a very negative reaction to this antibiotic. Extreme fatigue, continuing muscle weakness (after approximately 5 weeks), very vivid and frightening dreams, slow improvement in my bronchitis. I will never take this again.
I was perscribed Levaquin for bronchitis and it was completely effective. Now six months later I have developed a full compliment of the drugs side effects. Thrush, hives, yeast infection(vaginal), leg cramps and a knotted tendon. I am 65.
Levaquin (levofloxacin) for Pneumonia
I've been given this medicine twice - once for serious bronchitis/pneumonia that nearly required hospitialization. Since I am a well trained athlete, hospitalization for a lung infection was serious. Doctors tried several other drugs before the Levaquin, but Levaquin was best. Now dealing with a relatively minor bronchitis and have it again. I've never had any of the side effects others listed - bear in mind that weakness and headaches and many other symptoms might just be the progression of the disease and not due to the drug. It's hard to tell since each bout is different but compared to many other drugs, this is statistically a very good bet. If you have bronchitis or a respiratory infection, take your medicines with lots of fluids.
I had mild to severe coughing for several months, tried several other antibiotics and nothing worked until Lavaquin. I almost gave up. Two weeks ago went into the emergency room on Las Vegas with increased breathing and coughing problems. Blood tests, lung xrays, cat scan, oxygen, etc. etc. Two to three days after taking some prednisone, and a 10 day prescription for Levaquin all seems to have completely cleared up!!!
I had mild to severe coughing for several months, tried several other antibiotics and nothing worked until Lavaquin. I almost gave up. Two weeks ago went into the emergency room on Las Vegas with increased breathing and coughing problems. Blood tests, lung xrays, cat scan, oxygen, etc. etc. Two to three days after taking some prednisone, and a 10 day prescription for Levaquin all seems to have completely cleared up!!!
Levaquin (levofloxacin) for Sinusitis
My doctor always prescribes Levaquin for bad sinus infections and congestion because of my many drug allergies. I LOVE Levaquin. Within hours of the first dose all of the mucus in my head and/or chest starts to make a mass exodus. At times, the volume and swiftness that it drains can choke you -- but this medicine works and it works FAST. It's made me cough so hard I gag, but all of my coughs are super productive, if not overly so. I recommend this to anyone wanting to get better and back in the saddle at warp speed.
Levaquin was prescribed for a sinus infection. I had the same problem with sleeping the other two people had. No sleep at night for 2 days.
Was prescribed levaquin 750mg/5 day dose on June 22, 2009. First week no bad symptoms except for insomnia and nightmares. It did knock out sinus infection temporarily (10 days) but then sinusitis returned. It wasn't until week 3 after using this drug that I started noticing joint pain in elbows, knees, shoulders and lower back. It's November now and things haven't improved. Along with tendinitis symptoms I've also loss muscle strength in calf's, biceps and will experience burning in hamstrings after doing simple things like cutting my lawn. I hope this goes away or somebody offers a remedy to counter these effects.
I have a sinus infection that hasn't responded to any other treatments and I had decided to ignore it but 3 months have passed and it's gotten into my chest too. I was put on a Bacitrin and that did nothing so the Dr put me on Levaquin and thus far, I can say i haven't had any issues with sleep, I actually fell asleep watching TV last night and slept fairly well considering I have a ton of coughing congestion in my chest and that awful sinus discharge-we'll see how the rest goes/if it works.
Levaquin was prescribed for a sinus infection. I had the same problem with sleeping the other two people had. No sleep at night for 2 days.
Was prescribed levaquin 750mg/5 day dose on June 22, 2009. First week no bad symptoms except for insomnia and nightmares. It did knock out sinus infection temporarily (10 days) but then sinusitis returned. It wasn't until week 3 after using this drug that I started noticing joint pain in elbows, knees, shoulders and lower back. It's November now and things haven't improved. Along with tendinitis symptoms I've also loss muscle strength in calf's, biceps and will experience burning in hamstrings after doing simple things like cutting my lawn. I hope this goes away or somebody offers a remedy to counter these effects.
I have a sinus infection that hasn't responded to any other treatments and I had decided to ignore it but 3 months have passed and it's gotten into my chest too. I was put on a Bacitrin and that did nothing so the Dr put me on Levaquin and thus far, I can say i haven't had any issues with sleep, I actually fell asleep watching TV last night and slept fairly well considering I have a ton of coughing congestion in my chest and that awful sinus discharge-we'll see how the rest goes/if it works.
FDA Extends Marketing Exclusivity for Levaquin
The U.S. Food and Drug Administration (FDA) has granted LEVAQUIN(R) (levofloxacin) an additional six months of marketing exclusivity, known as "pediatric exclusivity." The action attaches to the U.S. patent covering LEVAQUIN, extending exclusivity from December 2010 to June 2011. This decision was based on five, company-sponsored pediatric studies conducted at the request of the FDA.
The studies included trials to determine the pharmacokinetic profile and the efficacy and safety of LEVAQUIN in children with community-acquired pneumonia (CAP) and recurrent and/or persistent acute otitis media. The studies were conducted in close collaboration with leaders in the pediatric and infectious disease communities and in consultation with the FDA. LEVAQUIN is not indicated for use in children and adolescents (under 18 years of age).
Since its U.S. introduction in 1996, LEVAQUIN has gained widespread use in the treatment of adults for a variety of bacterial infections caused by specific pathogens(1), including: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections (mild to moderate), chronic bacterial prostatitis, complicated and uncomplicated urinary tract infections (mild to moderate) and acute pyelonephritis (mild to moderate).
LEVAQUIN is available in 250 mg, 500 mg and 750 mg doses in both oral and I.V. formulations. The safety profile of LEVAQUIN is similar across doses. LEVAQUIN is marketed to healthcare providers by Ortho-McNeil, Inc., and PriCara, Unit of Ortho-McNeil, Inc.
Important Safety Information
The most common drug-related adverse events in U.S. clinical trials were nausea (1.5%) and diarrhea (1.2%). The safety and efficacy of LEVAQUIN in pediatric patients, adolescents (under 18), pregnant women, and nursing mothers have not been established. LEVAQUIN is contraindicated in persons with a history of hypersensitivity to LEVAQUIN, quinolone antimicrobial agents, or any other components of this product. Serious and occasionally fatal events, such as hypersensitivity and/or anaphylactic reactions, as well as some of unknown etiology have been reported in patients receiving therapy with quinolones, including LEVAQUIN. These reactions may occur following the first dose or multiple doses. The drug should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.
As with other quinolones, LEVAQUIN should be used with caution in patients with known or suspected central nervous system disorders, peripheral neuropathy, or in patients who have a predisposition to seizures.
Tendon ruptures that required surgical repair or resulted in prolonged disability have been reported in patients receiving quinolones, including LEVAQUIN, during and after therapy. This risk may be increased in patients receiving concomitant corticosteroids, especially the elderly. The quinolone should be discontinued in patients experiencing pain, inflammation, or rupture of a tendon.
Some quinolones, including LEVAQUIN, have been associated with prolongation of the QT interval, infrequent cases of arrhythmia, and rare cases of torsades de pointes. LEVAQUIN should be avoided in patients with known risk factors such as prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving class IA (quinidine, procainamide), or class III (amiodarone, sotalol) antiarrhythmic agents.
Antacids containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc, or Videx(R)* (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, should be taken at least 2 hours before or 2 hours after LEVAQUIN administration.
The studies included trials to determine the pharmacokinetic profile and the efficacy and safety of LEVAQUIN in children with community-acquired pneumonia (CAP) and recurrent and/or persistent acute otitis media. The studies were conducted in close collaboration with leaders in the pediatric and infectious disease communities and in consultation with the FDA. LEVAQUIN is not indicated for use in children and adolescents (under 18 years of age).
Since its U.S. introduction in 1996, LEVAQUIN has gained widespread use in the treatment of adults for a variety of bacterial infections caused by specific pathogens(1), including: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections (mild to moderate), chronic bacterial prostatitis, complicated and uncomplicated urinary tract infections (mild to moderate) and acute pyelonephritis (mild to moderate).
LEVAQUIN is available in 250 mg, 500 mg and 750 mg doses in both oral and I.V. formulations. The safety profile of LEVAQUIN is similar across doses. LEVAQUIN is marketed to healthcare providers by Ortho-McNeil, Inc., and PriCara, Unit of Ortho-McNeil, Inc.
Important Safety Information
The most common drug-related adverse events in U.S. clinical trials were nausea (1.5%) and diarrhea (1.2%). The safety and efficacy of LEVAQUIN in pediatric patients, adolescents (under 18), pregnant women, and nursing mothers have not been established. LEVAQUIN is contraindicated in persons with a history of hypersensitivity to LEVAQUIN, quinolone antimicrobial agents, or any other components of this product. Serious and occasionally fatal events, such as hypersensitivity and/or anaphylactic reactions, as well as some of unknown etiology have been reported in patients receiving therapy with quinolones, including LEVAQUIN. These reactions may occur following the first dose or multiple doses. The drug should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.
As with other quinolones, LEVAQUIN should be used with caution in patients with known or suspected central nervous system disorders, peripheral neuropathy, or in patients who have a predisposition to seizures.
Tendon ruptures that required surgical repair or resulted in prolonged disability have been reported in patients receiving quinolones, including LEVAQUIN, during and after therapy. This risk may be increased in patients receiving concomitant corticosteroids, especially the elderly. The quinolone should be discontinued in patients experiencing pain, inflammation, or rupture of a tendon.
Some quinolones, including LEVAQUIN, have been associated with prolongation of the QT interval, infrequent cases of arrhythmia, and rare cases of torsades de pointes. LEVAQUIN should be avoided in patients with known risk factors such as prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving class IA (quinidine, procainamide), or class III (amiodarone, sotalol) antiarrhythmic agents.
Antacids containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc, or Videx(R)* (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, should be taken at least 2 hours before or 2 hours after LEVAQUIN administration.
Generic Versions of Antibiotic Levaquin
The Food and Drug Administration said Monday it approved the first generic versions of Johnson & Johnson's antibiotic Levaquin, which treats bacterial infections that cause bronchitis or pneumonia.
The antibiotic, known generically as levofloxacin, also treats infections of the skin, sinuses, kidney, bladder and prostate. Regulators approved applications from 12 manufacturers for generic versions of the drug. Those companies include Akorn Inc., Dr. Reddy's Laboratories Ltd., Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals USA.
Levaquin is made by Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson.
I was perscribed Levaquin for a sinus infection. I had nausea and vomitting, and could not sleep at night. I also was itchy all over.
I've been taking levaquin for a sinus infection. I am on only my second dose, but yesterday after taking my first dose I felt immediate results. Much less nasal discharge than in the days and even hours prior. I had no problems with sleep, in fact that night was the first time I slept through the entire night in weeks, without even waking up to go to the bathroom.
The antibiotic, known generically as levofloxacin, also treats infections of the skin, sinuses, kidney, bladder and prostate. Regulators approved applications from 12 manufacturers for generic versions of the drug. Those companies include Akorn Inc., Dr. Reddy's Laboratories Ltd., Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals USA.
Levaquin is made by Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson.
I was perscribed Levaquin for a sinus infection. I had nausea and vomitting, and could not sleep at night. I also was itchy all over.
I've been taking levaquin for a sinus infection. I am on only my second dose, but yesterday after taking my first dose I felt immediate results. Much less nasal discharge than in the days and even hours prior. I had no problems with sleep, in fact that night was the first time I slept through the entire night in weeks, without even waking up to go to the bathroom.
Levaquin as an Antibacterial Treatment for Plague
The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.
Plague is extremely rare in most parts of the world, including the United States, with 1,000 to 2,000 cases worldwide each year. The three most common forms of plague are bubonic plague (infection of the lymph nodes), pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood).
Primarily an animal disease, plague can be spread to humans through bites from infected fleas, contact with infected animals or humans, or laboratory exposure. Yersinia pestis also is considered a biological threat agent, which could potentially be used as a bioterrorism agent.
The FDA approved Levaquin for plague under the agency's Animal Efficacy Rule, which allows efficacy findings from adequate and well-controlled animal studies to be used in cases where it is not feasible or ethical to conduct trials in humans. Because plague is such a rare disease, it would not be possible to conduct adequate efficacy trials in humans.
Levaquin's approval was based on an efficacy study conducted in African green monkeys that were infected with the plague bacterium in a laboratory setting. Animals were randomly selected to receive a 10-day regimen of Levaquin or placebo within six hours of the onset of fever after being infected. The primary endpoint was survival at the end of the study. Of the 17 monkeys treated with Levaquin, 94 percent survived. None of the seven monkeys treated with placebo survived.
"Today's approval broadens the available therapeutic treatments for plague," said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. "It also further demonstrates the usefulness of animal model studies to collect needed efficacy data in cases where human trials are not ethical or feasible."
Levaquin's safety has been evidenced by studies and post-marketing information for the drug's existing medical uses. Common side effects reported in more than 3 percent of patients were nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Serious but rare side effects include tendinitis and tendon rupture, worsening of muscle weakness in people with the neuromuscular disorder myasthenia gravis, allergic reactions, liver damage, abnormalities of the blood, effects on the nervous system, and abnormal heart rhythm. However, given that plague is a very serious and often deadly condition, the benefit of Levaquin for treating plague outweighs these potential risks.
The application for Levaquin was granted a priority review by the FDA. It joins streptomycin, doxycycline, tetracycline, and other antibacterial drugs in the tetracycline group as FDA-approved treatments for plague.
Plague is extremely rare in most parts of the world, including the United States, with 1,000 to 2,000 cases worldwide each year. The three most common forms of plague are bubonic plague (infection of the lymph nodes), pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood).
Primarily an animal disease, plague can be spread to humans through bites from infected fleas, contact with infected animals or humans, or laboratory exposure. Yersinia pestis also is considered a biological threat agent, which could potentially be used as a bioterrorism agent.
The FDA approved Levaquin for plague under the agency's Animal Efficacy Rule, which allows efficacy findings from adequate and well-controlled animal studies to be used in cases where it is not feasible or ethical to conduct trials in humans. Because plague is such a rare disease, it would not be possible to conduct adequate efficacy trials in humans.
Levaquin's approval was based on an efficacy study conducted in African green monkeys that were infected with the plague bacterium in a laboratory setting. Animals were randomly selected to receive a 10-day regimen of Levaquin or placebo within six hours of the onset of fever after being infected. The primary endpoint was survival at the end of the study. Of the 17 monkeys treated with Levaquin, 94 percent survived. None of the seven monkeys treated with placebo survived.
"Today's approval broadens the available therapeutic treatments for plague," said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. "It also further demonstrates the usefulness of animal model studies to collect needed efficacy data in cases where human trials are not ethical or feasible."
Levaquin's safety has been evidenced by studies and post-marketing information for the drug's existing medical uses. Common side effects reported in more than 3 percent of patients were nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Serious but rare side effects include tendinitis and tendon rupture, worsening of muscle weakness in people with the neuromuscular disorder myasthenia gravis, allergic reactions, liver damage, abnormalities of the blood, effects on the nervous system, and abnormal heart rhythm. However, given that plague is a very serious and often deadly condition, the benefit of Levaquin for treating plague outweighs these potential risks.
The application for Levaquin was granted a priority review by the FDA. It joins streptomycin, doxycycline, tetracycline, and other antibacterial drugs in the tetracycline group as FDA-approved treatments for plague.
Subskrybuj:
Posty (Atom)